Cart
sales@molnova.com
BC-1471
CAS No. 896683-84-4
BC-1471( —— )
Catalog No. M37579 CAS No. 896683-84-4
BC-1471 is a STAM-binding protein (STAMBP) deubiquitinase inhibitor that inhibits the inflammasome activity of NALP7 (NACHT, LRR, and PYD domains-containing protein 7) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 85 | Get Quote |
|
| 5MG | 130 | Get Quote |
|
| 10MG | 198 | Get Quote |
|
| 25MG | 329 | Get Quote |
|
| 50MG | 492 | Get Quote |
|
| 100MG | 659 | Get Quote |
|
| 200MG | 887 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBC-1471
-
NoteResearch use only, not for human use.
-
Brief DescriptionBC-1471 is a STAM-binding protein (STAMBP) deubiquitinase inhibitor that inhibits the inflammasome activity of NALP7 (NACHT, LRR, and PYD domains-containing protein 7) .
-
DescriptionBC-1471 is a STAM-binding protein (STAMBP) deubiquitinase inhibitor. BC-1471 inhibits NALP7 (NACHT, LRR and PYD domains-containing protein 7) inflammasome activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number896683-84-4
-
Formula Weight508.63
-
Molecular FormulaC27H32N4O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (98.30 mM; Ultrasonic )
-
SMILESO=C(CSc1nc2ccc(cc2c(=O)n1CCc1ccccc1)N1CCOCC1)NCC1CCCO1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bednash JS, et al. Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity. Nat Commun. 2017 May 11;8:15203.?
molnova catalog
related products
-
Tulmimetostat
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.
-
Cyanox CY 1790
Cyanox CY 1790 is an agent with antioxidant activity.
-
Astegolimab
Astegolimab (RG 6149) is a humanised IgG2 monoclonal antibody that targets the IL-33 receptor and inhibits IL-33 signalling. Astegolimab is used in the study of chronic obstructive pulmonary disease (COPD) and severe asthma in adults.
